International Consensus Criteria (2011)
The International Consensus Criteria (ICC), published in 2011 by Carruthers et al. (Carruthers et al. 2011), represents the most restrictive and biologically-oriented diagnostic framework. The ICC explicitly adopts the term “myalgic encephalomyelitis” (ME) to emphasize the neurological and immunological features of the disease, rejecting the broader “chronic fatigue syndrome” label as insufficiently specific.
1 Required Criteria
Diagnosis of myalgic encephalomyelitis requires post-exertional neuroimmune exhaustion (PENE) as the mandatory hallmark PLUS manifestations from at least THREE neurological impairment categories PLUS at least ONE manifestation from each of THREE immune/gastro-intestinal/genitourinary, energy metabolism/transport, and cardiovascular/respiratory/thermoregulatory categories.
A. Post-Exertional Neuroimmune Exhaustion (PENE) — MANDATORY
PENE is the central diagnostic feature and must be present.
Pathological inability to produce sufficient energy on demand with the following characteristics:
- Marked, rapid physical and/or cognitive fatigability in response to exertion
- Post-exertional symptom exacerbation: Disproportionate loss of physical and mental stamina, rapid muscular and cognitive fatigability, post-exertional malaise and/or pain, and tendency for other associated symptoms to worsen
- Post-exertional exhaustion: May occur immediately after activity or be delayed by hours or days
- Recovery period is prolonged: Usually 24 hours or longer
- Low threshold of physical and mental fatigability: Results in substantial reduction in pre-illness activity level
B. Neurological Impairments (at least THREE required)
Neurocognitive Impairments:
- Difficulty processing information (slowed thought, impaired concentration)
- Short-term memory loss
- Word-finding difficulty, impaired psychomotor function
- Perceptual/sensory disturbances (spatial instability, disorientation, inability to focus vision)
- Ataxia, muscle weakness, fasciculations
Pain:
- Headaches (new type, pattern, or severity)
- Significant pain in muscles, muscle-tendon junctions, joints, abdomen, or chest
- Pain can be migratory, generalized or localized, often changing in distribution
Sleep Disturbance:
- Disturbed sleep patterns: insomnia, prolonged sleep (hypersomnia), disturbed sleep/wake cycle
- Unrefreshing sleep: Patient awakens feeling exhausted regardless of sleep duration
Neurosensory, Perceptual, and Motor Disturbances:
- Sensory hypersensitivity: photophobia, hyperacusis, heightened sensitivities to odors, taste, touch
- Motor disturbances: muscle weakness, twitching, poor coordination, ataxia
C. Immune, Gastro-Intestinal, and Genitourinary Impairments (at least ONE)
- Immune: Tender lymph nodes, recurrent sore throat, recurrent flu-like symptoms, general malaise, new sensitivities to food/medications/chemicals
- Gastro-intestinal: Nausea, abdominal pain, bloating, irritable bowel syndrome
- Genitourinary: Urinary urgency or frequency, nocturia
D. Energy Production/Transportation Impairments (at least ONE)
- Cardiovascular: Inability to tolerate upright posture (orthostatic intolerance, neurally mediated hypotension, postural orthostatic tachycardia syndrome), palpitations, lightheadedness
- Respiratory: Dyspnea, labored breathing, air hunger
- Loss of thermostatic stability: Subnormal body temperature, marked diurnal fluctuation, sweating episodes, cold extremities, intolerance to heat or cold
- Intolerance to extremes of temperature
2 Phenotype Categories
The ICC proposes operational phenotype categories to capture disease heterogeneity:
- ME with Fibromyalgia: Patients meeting ME criteria with widespread pain and tenderness
- ME with Myofascial Pain Syndrome: Regional pain with trigger points
- ME with Postural Orthostatic Tachycardia Syndrome (POTS): ME with documented autonomic dysfunction
- ME with Irritable Bowel Syndrome: ME with prominent gastrointestinal manifestations
- ME with Multiple Chemical Sensitivity: ME with sensitivity to environmental chemicals
These categories are not mutually exclusive; patients may meet criteria for multiple phenotypes simultaneously.
3 Duration and Exclusions
- Duration: Symptom persistence for at least 6 months
- Pediatric Exception: In children and adolescents, 3 months may be sufficient for diagnosis given the urgency of early intervention
- Exclusions: Active disease processes that explain most symptoms must be ruled out (e.g., untreated hypothyroidism, obstructive sleep apnea)
- Comorbidities allowed: Fibromyalgia, myofascial pain, temporomandibular disorder, irritable bowel syndrome, interstitial cystitis, Raynaud phenomenon, mitral valve prolapse, migraines can coexist with ME
4 Strengths and Limitations
The ICC framework has several advantages:
- Biological orientation: Emphasizes objective neurological and immune manifestations rather than subjective fatigue
- Post-exertional neuroimmune exhaustion as mandatory: Recognizes PEM as the pathognomonic feature
- Multi-system requirement: Requires manifestations across multiple physiological systems, increasing specificity
- Phenotype categories: Acknowledges heterogeneity and common comorbidities
- Higher specificity: More restrictive than Canadian Consensus or Fukuda, resulting in more homogeneous research cohorts
The restrictiveness of ICC creates challenges:
- Excludes mild cases: Patients with genuine ME/CFS who do not yet manifest symptoms across all required categories may be missed
- Clinical impracticality: Detailed assessment across 8 categories requires extensive clinical time and expertise
- Reduced sensitivity: Systematic review found ICC identifies only 60% of patients meeting Canadian Consensus Criteria (Brurberg et al. 2014)
- Formal set-theoretic relationship: \(\text{ICC} \subset \text{Canadian Consensus} \subset \text{Fukuda}\) — ICC is the most restrictive subset
- Delayed diagnosis risk: Waiting for full symptom constellation may delay intervention during the critical 6-month window
(See Case Definition Heterogeneity for a full methodological analysis of how case definition choice shapes research outcomes.)
5 Research and Clinical Application
The ICC is optimal for research where high specificity and phenotypic homogeneity are priorities, reducing heterogeneity that can obscure treatment signals. However, for clinical practice, the more inclusive Canadian Consensus Criteria or IOM criteria are preferred to avoid missing early-stage or mild cases that would benefit from intervention.